✦ LIBER ✦

A phase I trial of fazarabine in refractory pediatric solid tumors

✍ Scribed by Mark L. Bernstein; V. Michael Whitehead; Holcombe Grier; Ron Dubowy; Vita Land; Susan Devine; Sharon Murphy; Faith Kung

Publisher: Springer US
Year: 1993
Tongue: English
Weight: 289 KB
Volume: 11
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00874429

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I study of acivicin in refractor

A Phase I study of acivicin in refractory pediatric solid tumors

✍ Sylvain Baruchel; Mark Bernstein; V. Michael Whitehead; Susan Devine; Beverly Be 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 444 KB

Phase I trial of trimetrexate in pediatr

Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study

✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

Phase II trial of indicine N-oxide in re

Phase II trial of indicine N-oxide in relapsed pediatric solid tumors

✍ James S. Miser; William A. Smithson; William Krivit; Carla Hughes; Dianne Davis; 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 280 KB

We used indicine N-oxide to treat 46 children with malignant solid tumors: 17 with osteosarcoma, 12 with neuroblastoma, 13 with a brain tumor, and 4 with other miscellaneous tumors. The efficacy and toxicity of the drug was assessed at the dose of 2000 mg/m2/day for five consecutive days. None of th

Phase I study of fotemustine in pediatri

Phase I study of fotemustine in pediatric patients with refractory brain tumors

✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res

Phase I trial of a 72-h continuous-infus

Phase I trial of a 72-h continuous-infusion schedule of fazarabine

✍ Robert Amato; Dah Ho; Sue Schmidt; Irwin H. Krakoff; Martin Raber 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 346 KB

A phase II trial of paclitaxel in refrac

A phase II trial of paclitaxel in refractory germ cell tumors

✍ Alan B. Sandler; Antonios Cristou; Susan Fox; Stephen D. Williams; Craig R. Nich 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

over 24 hours every 21 days without growth factor support. The median age of the patients was 32.5 years (range, 18-49 years). The testis was the primary site of Genitourinary Oncology Program, Indiana Unitumor for 13 patients (72%) and the tumor was extragonadal in 5 patients (28%).